Alcor Energy, LLC Seeks Chapter 11 Bankruptcy Protection

Alcor Energy, LLC commenced a Chapter 11 bankruptcy case in the District of Delaware on December 19, 2018.

Alcor Energy operates a portable turbine generator business.  Its core customers are oil and gas operators who rent generators to obtain power in remote places with limited access to conventional power grids.

Ultimately, many factors led to the deterioration of Alcor’s business performance. These include litigation claims, quality control issues, excessive operational and manufacturing costs, unprofitable customer contracts, deferred maintenance costs, and customer dissatisfaction. In the midst of these challenges, investor relationships also became strained.

To obtain an independent perspective, Alcor engaged Neil Gilmour III as an independent manager. Mr. Gilmour has extensive experience counseling companies through financial and operational turnarounds.  Together with other members of Alcor’s management, Mr. Gilmour determined that a Chapter 11 process would be Alcor’s best path forward.

Alcor has announced that it intends to file a small business plan of reorganization through which is funded debt to its lender, Ocho Ventura, LLC, will be cancelled, and the reorganized company will emerge as a significantly delevered enterprise. Ocho will receive 100% of the membership interests in the reorganized company, as well as deferred payment on a portion of the amounts owed to it, through a debt-for-equity swap.

The Debtor has asked that no official committee of unsecured creditors be appointed in this case.

The Case No. is 18-12839. Additional information about the bankruptcy filing can be found here.

Do you have questions or are you looking for additional information? Feel free to  contact me!

Mette K.

USA Gymnastics Seeks Bankruptcy Protection in #MeToo Fallout

Facing 100 lawsuits from more than 350 sexual-assault victims of team physician Larry Nassar, Indianapolis-based USA Gymnastics filed for chapter 11 protection today. The case is pending in the Bankruptcy Court for the Southern District of Indiana.

“We owe it to the survivors to resolve, fully and finally, claims based on the horrific acts of the past and, through this process, seek to expedite resolution and help them move forward,” said Kathryn Carson, the newly-elected chair of USA Gymnastics’ Board of Directors.  In addition, the Chapter 11 filing will put on hold the U.S. Olympic Committee’s effort to dismantle the sport’s governing body, according to Carson, providing “breathing room” for the organization to continue running the sport at a grassroots and national level.  The full press release is available here.

But as reported by NBC News, lawyer John Manly, who represents 180 alleged victims of Nassar, has this to say: “The leadership of USA Gymnastics has proven itself to be both morally and financially bankrupt” and the bankruptcy filing will block the victims’ “ongoing efforts to discover the truth about who at USA Gymnastics and the U.S. Olympic Committee knew about Nassar’s criminal conduct and failed to stop it.”

The case number is 18-09108.  The bankruptcy petition is available for download.

Mette K.



Argos Therapeutics Files Bankruptcy to Pursue a Sale

 Argos Therapeutics filed for chapter 11 protection in Delaware on Nov. 30th with a proposed buyer in hand. The bankruptcy follows the termination of an unsuccessful phase 3 clinical trial of its most advanced cancer-treatment product. Now, Argos seeks to run a going-concern sale process with Cellscript, LLC as a “stalking horse” buyer.  Argos values Cellscript’s opening bid at $3.8 million.

Who Is Argos Therapeutics?

Argos is an immunotherapy company based in North Carolina. It is publicly traded, with shares trading on the NASDAQ until April 23. After its common stock was de-listed as of April 25, Argos transferred its common stock to the OTCQB Venture Market.

Argos focuses on developing individualized immunotherapies to treat cancer and infectious diseases. The company derives its primary revenue from third-party license agreements and government grants. But the company has been far from profitable, with a net loss of $40.6 million for 2017.

The company built its immunotherapies on its Arcelis® technology platform.

Arcelis is a precision immunotherapy technology that captures the spectrum of mutated and variant antigens that are specific to each patient’s individual disease . . . to overcome immunosuppression by enabling specifically targeted, durable memory T-cells without adjuvants that may be associated with toxicity.

Confused?  Here’s a helpful diagram.


Ummm…. Still confused? If you have 15 minutes, Jeff Abbey provides a thorough explanation here.

Practically speaking, a buyer might use the Arcelis platform to treat a range of different cancers and infectious diseases. And according to Argos (notwithstanding its bankruptcy), the platform is valuable because it may circumvent manufacturing and commercialization challenges that have impeded other personalized immunotherapies.

The Proposed Sale to Cellscript

Argos has engaged in an extensive marketing effort to capitalize on its intellectual property, its manufacturing capabilities, and its position as a publicly traded entity.  Ultimately, Cellscript – one of Argos’ largest unsecured creditors – presented a purchase offer. The bid includes $1.675 million in cash, cure costs and assumed liabilities valued at no less than $1.4 million, and the “release” of Cellscript’s $2 million unsecured claim against Argus, valued at a minimum of $700,000.

Argos has proposed a $75,000 breakup fee and a $75,000 expense reimbursement. Initial overbids must total at least $4,095,330, with subsequent overbid increments of at least $100,000.  And it proposes the following sale timeline:

  • Bid deadline: Jan. 16, 2019
  • Auction: Jan. 22, 2019

The court has scheduled the bid procedures motion for hearing on Dec. 20, 2018.

Case Information

Argos is represented by Landis Rath & Cobb as bankruptcy counsel, Wilmer Cutler Pickering Hale and Dorr as special corporate counsel, and SSG Advisors as investment banker. Judge Kevin Carey is presiding over the case (#18-12714).

Mette K.